Patent application number | Description | Published |
20100297175 | Mutations in a toll-like receptor motif in the NS4B of classical swine fever virus strain brescia influences virulence in swine - NS4B is one of the non-structural proteins of classical swine fever virus. By using functional genetics, we have discovered, in the predicted amino acid sequence of NS4B of CSFV strain Brescia, a motif that resembles those found in the toll-like receptor (TLR) proteins, a group of host cell proteins involved in the development of anti-viral mechanisms. We have located the TLR motif in two groups of amino acid triplets at amino acid positions 2531-3 (residues IYK) and 2566-8 (residues VGI) of the CSFV NS4B glycoprotein. We have constructed a recombinant CSFV (derived from an infectious clone containing the genetic information of the highly virulent strain Brescia) containing amino acid substitutions in the three amino acid residues at positions 2566, 2567 and 2568, where the VGI triplet has been replaced by an AAA triplet inside the NS4B glycoprotein. The obtained virus, named NS4B-VGIv, was completely attenuated in swine, showing a limited ability in spreading during the infection in vivo. Although attenuated, NS4B-VGIv efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection. | 11-25-2010 |
20110177123 | Recombinant Live Attenuated Foot-and-Mouth Disease (FMD) Vaccine Containing Mutations in the L Protein Coding Region - Previously we have identified a conserved domain (SAP, for SAF-A/B, Acinus, and PIAS) in the foot-and-mouth disease virus (FMDV) leader (L) protein coding region that is required for proper sub-cellular localization and function. Mutation of isoleucine 55 and leucine 58 to alanine (I55A, L58A) within the SAP domain resulted in a viable virus that displayed a mild attenuated phenotype in cell culture, along with altered sub-cellular distribution of L and failure to induce degradation of the transcription factor nuclear factor kappa-B. Here we report that inoculation of swine and cattle with this mutant virus results in the absence of clinical disease, the induction of a significant FMDV-specific neutralizing antibody response, and protection against subsequent homologous virus challenge. Remarkably, swine vaccinated with SAP mutant virus are protected against wild type virus challenge as early as two days post-vaccination suggesting that a strong innate as well as adaptive immunity is elicited. This variant could serve as the basis for construction of a live-attenuated FMD vaccine candidate. | 07-21-2011 |
20120164171 | Antiviral Activity of Bovine Type III Interferon Against Foot-and-Mouth Disease Virus - Interferons are the first line of defense against viral infections and administration of interferons as biotherapeutics has been demonstrated to be effective in controlling several viral infections. Here we report for the first time the identification and characterization of a member of the bovine type III IFN family, boIFN-λ3. We have expressed boIFN-λ3 using a recombinant replication defective human adenovirus type 5 (Ad5) and demonstrated antiviral activity against foot-and-mouth disease virus (FMDV) and vesicular stomatitis virus (VSV) in bovine cells in vitro. Furthermore, we have tested the efficacy of boIFN-λ3 against FMDV in vivo by inoculation of cattle with Ad5-boIFN-λ3 followed by intradermolingual or aerosol virus challenge. Our results demonstrate that the type III IFN family is conserved in bovines and that treatment of cattle with boIFN-λ3 alone or in combination with IFN-α is able to confer delayed and reduced severity of FMD. Furthermore inoculation with Ad5-boIFN-λ3 alone conferred full protection against aerosol challenge for at least 7 days after administration suggesting that type III IFN used in combination with FMD vaccines could fill one of the current gaps in emergency vaccination against FMDV. | 06-28-2012 |
Patent application number | Description | Published |
20090022894 | Thermally Resistant Anaerobically Curable Compositions - The present invention relates to anaerobically curable compositions demonstrating resistance to elevated temperature conditions. | 01-22-2009 |
20090298970 | (METH)ACRYLATES COMPOSITIONS CONTAINING DISPERSIONS OF CORE SHELL RUBBERS IN (METH)ACRYLATES - The present invention provides a (meth)acrylate composition comprising a (meth)acrylate component; and a core shell rubber component having a particle size in the range of 3 nm to 1,000 nm dispersed in a curable (meth)acrylate matrix. | 12-03-2009 |
20100006208 | ANAEROBICALLY CURABLE COMPOSITIONS - Dry-to-the-touch compositions containing a curable polymeric matrix and a curable anaerobic composition present within the polymeric matrix are disclosed. In a particularly desirable form, the compositions are moisture curable. The compositions are non-flowable at high temperatures and have an improved solvent resistance once cured. | 01-14-2010 |
20100061823 | DRY-TO-THE-TOUCH ANAEROBICALLY CURABLE COMPOSITIONS AND PRODUCTS MADE THEREFROM - Dry-to-the-touch compositions containing a polymeric matrix and a anaerobically curable component present within the polymeric matrix are disclosed. In a particularly desirable form, the compositions are moisture curable. The compositions are non-flowable, at high temperatures, and have an improved solvent resistance once cured. | 03-11-2010 |
20100086796 | THERMALLY RESISTANT ANAEROBICALLY CURABLE COMPOSITIONS - The present invention relates to anaerobically curable compositions demonstrating resistance to elevated temperature conditions. | 04-08-2010 |
20120231286 | ANAEROBICALLY CURABLE COMPOSITIONS - The present invention relates to anaerobically curable compositions containing a benzoxazine component and which demonstrates resistance to elevated temperature conditions and/or accelerated cure speed. | 09-13-2012 |
20140107283 | CONTROLLED RADICAL POLYMERIZATION OF (METH)ACRYLATE MONOMERS - Living radical polymerization processes, reaction products of such processes, and compositions containing such reaction products are provided. More particularly, a living radical polymerization of (meth)acrylic acid monomers employing having a defined order of introduction of the reactants and/or a specific set of reaction conditions, is provided. | 04-17-2014 |
20150086783 | RESIN COMPOSITIONS FOR COATING SUBSTRATES TO IMPROVE SEALING PERFORMANCE - The present invention is directed to compositions useful for sealing substrates and substrates coated therewith. Additionally, methods of sealing and improving sealing performance using such compositions are provided. | 03-26-2015 |
Patent application number | Description | Published |
20080262055 | Macrocyclic Acyl Guanidines as Beta-Secretase Inhibitors - There is provided a series of heterocyclic-containing macrocyclic acyl guanidines of Formula (I) or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, | 10-23-2008 |
20120238539 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS - A compound of Formula I is set forth, including pharmaceutically acceptable salts thereof: | 09-20-2012 |
20120245176 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS - A compound of Formula I is set forth, including pharmaceutically acceptable salts thereof: | 09-27-2012 |
20140011700 | THREE-DIMENSIONAL STRUCTURE OF H1N1 NUCLEOPROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUNDS - The binding mode of the antiviral compounds have been characterized through a variety of biophysical and structural studies, elaborating on the proposed aggregation mechanism of action. We demonstrate the direct binding of these antiviral compounds to NP using thermal shift enhancement assay (TSE) and NMR. In addition, we have completed a detailed analysis of the oligomerization mechanism of action using dynamic light scattering, analytical ultracentrifugation, and surface plasmon resonance (SPR). Structure determination using x-ray crystallography confirmed the proposed compound-induced oligomerization mechanism of action. The co-crystal structure revealed that two compounds bound in an anti-parallel fashion bridging two NP monomers, inducing a novel non-native NP oligomer. Taken together, our data suggest a complex binding mode in which the compounds bind NP specifically in stoichiometric fashion inducing the formation of an NP oligomer without obstructing the RNA binding pocket or interfering with the native NP homo-oligomerization. | 01-09-2014 |
Patent application number | Description | Published |
20120032748 | Systems and Methods of Ripple Reduction in a DC/DC Converter - Systems and devices for ripple reduction in a DC/DC converter are presented. The disclosed systems and methods enable ripple reduction in discontinuous conduction mode (DCM) operation. In DCM, the inductor current peak to peak ripple may be reduced based on the load current. To achieve the reduction of the inductor peak to peak current ripple, a digital counter is used to count the time between consecutive PWM pulses. The digital output of the counter is used to control the pulse width modulation. As the digital output of the counter increases, the PWM on-time decreases. Since the PWM pulse is demanded by the load in DCM mode, the peak to peak inductor ripple is modulated by the counter, or, in turn, modulated by the load current. | 02-09-2012 |
20120038331 | Systems and Methods of Smooth Light Load Operation in a DC/DC Converter - Systems and devices for smooth light load operation in a DC/DC converter are presented. The disclosed systems and methods enable smooth discontinuous conduction mode (DCM)/continuous conduction mode (CCM) transition. The disclosed systems and methods of smooth light load operation in a DC/DC converter may also avoid the generation of sub-harmonics during light load operation. In an example embodiment, a rising ramp is used to control the ON time of the converter oscillator, while a falling ramp controls the OFF time. During DCM operation, the minimum value of the falling ramp is clamped. The clamping of the falling ramp ensures a substantially similar level of the error amplifier output in both CCM and DCM and avoids disturbances caused by a difference in the error amplifier outputs between the modes. | 02-16-2012 |
20140266112 | POWER REGULATOR SYSTEM WITH ADAPTIVE RAMP SIGNAL GENERATOR - One embodiment includes a power regulator system. The system includes a switch control stage configured to generate at least one activation signal based on a pulse-width modulation (PWM) signal and to control a respective at least one switch to generate an output voltage. The system also includes a feedback stage configured to generate the PWM signal based on a ramp signal and a feedback voltage that is based on the output voltage. The system further includes a ramp generator stage configured to adaptively generate the ramp signal based on the output voltage and based on the at least one activation signal. | 09-18-2014 |
Patent application number | Description | Published |
20130262473 | SYSTEMS, METHODS, AND APPARATUS FOR REVIEWING FILE MANAGEMENT - Systems, apparatus, methods and articles of manufacture provide for reviewing the management of one or more business files. According to some embodiments, methods may include determining a plurality of file review criteria, determining a plurality of file review questions, determining a respective maximum potential review score for each file review question, determining respective responses for the file review questions, adjusting (if necessary) one or more of the maximum potential review scores, and/or determining at least one review score for each file review question answered. Some embodiments may provide for determining a respective review score for a file for each of one or more predetermined file review criteria. | 10-03-2013 |
20140012603 | CAPACITY PLANNING AND MODELING FOR OPTIMIZATION OF TASK OUTCOMES - Systems and methods for optimizing outcomes in view of various business scenarios are based on a unique quantification of work and estimate of task duration, which may be used to develop a measure of the work required to complete a task. This measure may be compared to forecasted work and used to allocate resources accordingly. Additionally, optimal outcomes may be identified subject to any classification, such as by class of worker, type of task, location of task, and/or size of work unit. | 01-09-2014 |
Patent application number | Description | Published |
20080212172 | Image Processing Method for a Microscope System - An embodiment is disclosed for performing the image processing for analyzing the results of a fluorescence in situ hybridization (FISH) microscopic automated sample analysis to determine specific chromosomal characteristics. | 09-04-2008 |
20080212865 | Image Processing Method for a Microscope System - An embodiment is disclosed for performing the image processing for analyzing the results of a fluorescence in situ hybridization (FISH) microscopic automated sample analysis to determine specific chromosomal characteristics. | 09-04-2008 |
20090250629 | Methods for Detecting Fluorescent Signals in a Biological Sample - Operational means for automatic microscopic detection and analysis of fluorescent signals from a treated biological sample. | 10-08-2009 |
20100322064 | METHOD FOR DETECTING FLUORESCENT SIGNALS IN A BIOLOGICAL SAMPLE - A method for automated microscopic analysis wherein the test protocol is obtained from interrogatable data affixed to each microscope slide. The method further comprises the algorithms that implement the test protocol. | 12-23-2010 |
20110079640 | METHODS FOR DETECTING FLUORESCENT SIGNALS IN A BIOLOGICAL SAMPLE - A method for automated microscopic analysis wherein the test protocol is obtained from interrogatable data affixed to each microscope slide. The method further comprises the algorithms that implement the test protocol. | 04-07-2011 |
20110317904 | IMAGE PROCESSING METHOD FOR A MICROSCOPE SYSTEM - An embodiment is disclosed for performing the image processing for analyzing the results of a fluorescence in situ hybridization (FISH) microscopic automated sample analysis to determine specific chromosomal characteristics. | 12-29-2011 |
Patent application number | Description | Published |
20090148539 | Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease - The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease. | 06-11-2009 |
20090149410 | Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease - The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease. | 06-11-2009 |
20090162347 | METHODS, COMPOSITIONS, AND KITS RELATING TO CHITINASES AND CHITINASE-LIKE MOLECULES AND INFLAMMATORY DISEASE - The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease. | 06-25-2009 |
20130136751 | Methods, Compositions and Kits Relating to Chitnases and Chitnase-Like Molecules and Inflammation Disease - The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease. | 05-30-2013 |